Social support and brain function are mediators between trauma during youth and major depressive disorder (MDD), suggests a study presented in a poster at the virtual 2021 American Psychiatric Association Annual Meeting.
Somatically healthy people with major depressive disorder showed a median 2 years’ excess cellular aging, compared with age-matched healthy control subjects, in a study published online in Translational Psychiatry.
Although long suspected of causing depression and other psychiatric symptoms in patients undergoing treatment for cardiovascular disease, beta-blockers are not associated with increased risk of depression, according to a systematic review and meta-analysis.
More than half of 3904 US adults with previous COVID-19 illness met criteria for moderate or greater symptoms of major depressive disorder months later, according to a study published online in a research letter in JAMA Network Open.
Social anxiety symptoms in children exposed to maternal major depressive disorder (MDD) increased children’s risk of developing depressive symptoms over time, according to a study published in the Journal of Adolescence.
Psych Congress cochair Charles Raison, MD, will give a virtual keynote speech August 20, 2020, for the University of Louisville Depression Center’s annual benefit. The event is free and open to the public.
AXS-05, an investigational modulated-delivery tablet combining dextromethorphan and bupropion, significantly improved symptoms of depression in patients with major depressive disorder (MDD) in a recent phase 3 trial, announced developer Axsome Therapeutics Inc.